Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20022007 | 0.89 | CYP3A4 (0.41) | TDP1ALDH1A1CYP3A4HPGDGABRA1 | |
| SCHEMBL17764871 | 0.80 | GABRA1 (0.37) | TDP1ALDH1A1CYP3A4HPGDGABRA1 | |
| SCHEMBL374359 | 0.79 | ALDH1A1 (0.42) | TDP1ALDH1A1CYP3A4HPGDGABRA1 | |
| SCHEMBL28096921 | 0.74 | ALDH1A1 (0.49) | TDP1ALDH1A1CYP3A4HPGDGAA | |
| SCHEMBL10316848 | 0.74 | CYP3A4 (0.49) | TDP1ALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL5770742 | 0.73 | ALDH1A1 (0.47) | TDP1ALDH1A1CYP3A4HPGDGABRA1 | |
| SCHEMBL1457541 | 0.73 | ALDH1A1 (0.56) | TDP1ALDH1A1CYP3A4HPGDGAA | |
| SCHEMBL8163649 | 0.72 | CYP3A4 (0.66) | TDP1ALDH1A1CYP3A4HPGDGAA | |
| SCHEMBL583613 | 0.72 | GABRA1 (0.42) | TDP1GABRA1GABRB2MAPK1 | |
| SCHEMBL3837324 | 0.72 | MAPK1 (0.50) | TDP1ALDH1A1CYP3A4HPGDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | claimed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | claimed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | claimed |
| EP-4676486-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | QED THERAPEUTICS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025090870-A1 | INFIGRATINIB AND METABOLITES THEREOF FOR USE IN METHODS OF TREATING SKELETAL DISORDERS | QED THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250101002-A1 | DEUTERATED INFIGRATINIB COMPOUNDS | Ferro Therapeutics, Inc. | 2025-03-27 | — | — | US | disclosed |
| WO-2024186882-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024093681-A1 | USE OF INFIGRATINIB IN TREATING GASTRIC CANCER AND ADENOCARCINOMA | QED医药股份有限公司 | 2024-05-10 | — | — | WO | disclosed |
| CN-117982507-A | Use of inflictinib in the treatment of gastric and adenocarcinoma | QED医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-2509963-A1 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF. | Novartis AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245182-A1 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1--1-METHYL-UREA AND SALTS THEREOF | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2011071821-A1 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF. | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357632-B2 | Methods of treating cholangiocarcinoma | KRAS, SLC10A2, SLC10A1 | TDP1 4587/4885ALDH1A1 957/4885CYP3A4 4323/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | TDP1 915/4885ALDH1A1 4285/4885CYP3A4 2987/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | TDP1 915/4885ALDH1A1 4285/4885CYP3A4 2987/4885 |
| US-20120245182-A1 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1--1-METHYL-UREA AND SALTS THEREOF | RCC1, SLC14A1, UBLCP1 | TDP1 814/4885ALDH1A1 2835/4885CYP3A4 2032/4885 |
| US-20250101002-A1 | DEUTERATED INFIGRATINIB COMPOUNDS | FGFR3, FGFR1, ABL1 | TDP1 1925/4885ALDH1A1 2682/4885CYP3A4 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.